Giant cell arteritis
Giant cell arteritis | |
---|---|
Other names | Temporal arteritis, cranial arteritis, bisphosphonates, proton-pump inhibitor[4] |
Prognosis | Life expectancy (typically normal)[4] |
Frequency | ~ 1 in 15,000 people a year (> 50 years old)[2] |
Giant cell arteritis (GCA), also called temporal arteritis, is an
The cause is unknown.
Treatment is typical with high doses of
It affects about 1 in 15,000 people over the age of 50 per year.
Signs and symptoms
Common symptoms of giant cell arteritis include:
- bruits
- fever
- headache[9]
- tenderness and sensitivity on the scalp
- jaw claudication (pain in jaw when chewing)
- tongue claudication (pain in tongue when chewing) and necrosis[10][11]
- reduced visual acuity (blurred vision)
- acute visual loss(sudden blindness)
- diplopia (double vision)
- acute tinnitus (ringing in the ears)
- polymyalgia rheumatica (in 50%)[12]
The inflammation may affect blood supply to the
Giant cell arteritis may present with atypical or overlapping features.[14] Early and accurate diagnosis is important to prevent ischemic vision loss. Therefore, this condition is considered a medical emergency.[14]
While studies vary as to the exact relapse rate of giant cell arteritis, relapse of this condition can occur.[15] It most often happens at low doses of prednisone (<20 mg/day), during the first year of treatment, and the most common signs of relapse are headache and polymyalgia rheumatica.[15]
Associated conditions
The
The disorder may co-exist (in about half of cases) with polymyalgia rheumatica (PMR),[12] which is characterized by sudden onset of pain and stiffness in muscles (pelvis, shoulder) of the body and is seen in the elderly. GCA and PMR are so closely linked that they are often considered to be different manifestations of the same disease process. PMR usually lacks the cranial symptoms, including headache, pain in the jaw while chewing, and vision symptoms, that are present in GCA.[17]
Giant cell arteritis can affect the aorta and lead to aortic aneurysm and aortic dissection.[18] Up to 67% of people with GCA having evidence of an inflamed aorta, which can increase the risk of aortic aneurysm and dissection.[18] There are arguments for the routine screening of each person with GCA for this possible life-threatening complication by imaging the aorta. Screening should be done on a case-by-case basis based on the signs and symptoms of people with GCA.[18]
Mechanism
The pathological mechanism is the result of an inflammatory cascade that is triggered by an as of yet undetermined cause resulting in
Diagnosis
Physical exam
- Palpation of the head reveals prominent temporal arteries with or without pulsation.[20]
- The temporal area may be tender.[20]
- Decreased pulses may be found throughout the body[20]
- Evidence of ischemia may be noted on fundal exam.[20]
- Bruits may be heard over the subclavian and axillary arteries[20]
Laboratory tests
- Erythrocyte sedimentation rate,[21] an inflammatory marker, >60 mm/hour (normal 1–40 mm/hour)
- C-reactive protein, another inflammatory marker, may be elevated[21]
- LFTs, liver function tests, are abnormal particularly raised ALP- alkaline phosphatase
- Plateletsmay also be elevated
Biopsy
The
Medical imaging
Radiological examination of the temporal artery with ultrasound yields a halo sign. Contrast-enhanced brain MRI and CT are generally negative in this disorder. Recent studies have shown that 3T MRI using super high resolution imaging and contrast injection can non-invasively diagnose this disorder with high specificity and sensitivity.[24]
Early recognition
Women and men approximately 45 years old and who suffer from several complaints (at least 5 of the 16 symptoms)[25] listed below could have giant cell arteritis.
- Fatigue and apathy
- Stiffness in joints and/or muscles
- Painful jaws when chewing
- Sensitive scalp
- Physical malaise and/or weakness
- Bloated arteries of the temples
- Headaches, migraine
- Tongue problems
- Bleakness, depression
- Changed eyesight
- Poor or lack of appetite
- Reduced eyesight, blindness
- Unusual loss of weight
- A temperature
- Unusual perspiration
- Night sweats
Treatment
GCA is considered a
Epidemiology
Giant cell arteritis typically only occurs in those over the age of 50;[4] particularly those in their 70s.[21] It affects about 1 in 15,000 people over the age of 50 per year.[2] It is more common in women than in men, by a ratio of 2:1,[4] and more common in those of Northern European descent, as well as in those residing further from the Equator.[5]
Disease impact
Giant cell arteritis and its treatment impact on people's lives because of symptoms, adverse effects of GCs and disruption to normal life.[36] People with GCA have previously ranked ‘losing sight in both eyes permanently’, ‘having intense or severe pain’ and ‘feeling weak, tired or exhausted’ as important quality of life domains.[37] Generic measures of disease impact such as SF36 may not always capture the disease specific aspects of GCA impact such as visual loss or systemic complications.[38] The Outcome Measures in Rheumatology (OMERACT) Large Vessel Vasculitis Working Group have identified the need for a disease-specific patient-reported outcome measure (PROM) for GCA.[39] Recently, a new disease specific measure of health-related quality of life in GCA has been developed.[40][41] The GCA-PRO has been shown to have robust validity and reliability in a cross-sectional study and can discriminate between different sub-groups of patients. This is likely going to help to capture the impact of disease and treatment in clinical trials and clinical practice.[41]
Terminology
The terms "giant cell arteritis" and "temporal arteritis" are sometimes used interchangeably, because of the frequent involvement of the temporal artery. However, other large vessels such as the aorta can be involved.[42] Giant-cell arteritis is also known as "cranial arteritis" and "Horton's disease".[43] The name (giant cell arteritis) reflects the type of inflammatory cell involved.[44]
References
- ^ ISBN 978-0-12-803268-8. Archivedfrom the original on 2017-10-22.
- ^ a b c d e "Orphanet: Giant cell arteritis". www.orpha.net. Archived from the original on 14 September 2017. Retrieved 14 September 2017.
- ^ a b "Giant Cell Arteritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. 13 April 2017. Archived from the original on 22 October 2017. Retrieved 21 October 2017.
- ^ PMID 24988557.
- ^ ISBN 9780323242875. Archivedfrom the original on 2017-10-22.
- ISBN 978-0-323-08163-4. Archivedfrom the original on 2017-10-22.
- S2CID 20891451.
- ^ "Giant Cell Arteritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. 13 April 2017. Archived from the original on 22 October 2017. Retrieved 21 October 2017.
- PMID 18711459.
- PMID 18499311.
- ^ PMID 21176820.
- ^ a b Hunder GG. "Polymyalgia rheumatica and giant cell (temporal) arteritis". uptodate.com. Wolters Kluwer. Archived from the original on 25 September 2015. Retrieved 23 September 2015.
- ^ Hayreh (April 3, 2003). "Ocular Manifestations of GCA". University of Iowa Health Care. Archived from the original on 2007-10-25. Retrieved 2007-10-15.
- ^ PMID 25288850.
- ^ a b "UpToDate". www.uptodate.com. Retrieved 2019-11-25.
- PMID 25695965.
- ^ "Giant cell arteritis". BMJ Best Practice. Retrieved 2019-11-25.
- ^ S2CID 3747982.
- PMID 24988557.
- ^ a b c d e "Giant Cell Arteritis". The Lecturio Medical Concept Library. 26 November 2020. Retrieved 23 July 2021.
- ^ PMID 31970405.
- PMID 28601496.
- S2CID 20149393.
- PMID 17885247.
- ^ "Symptomatix Home". www.symptomatrix-eng.eu. Retrieved 2023-05-07.
- PMID 16987903.
- ^ "BestBets: Steroids and Temporal Arteritis". Archived from the original on 2009-02-27.
- PMID 11520757.
- S2CID 30995207.
- PMID 26611557.
- S2CID 39396172.
- PMID 25087045.
- ^ "Press Announcements - FDA approves first drug to specifically treat giant cell arteritis". www.fda.gov. Retrieved 10 February 2018.
- ^ S2CID 4227514.
- ^ PMID 31291180.
- PMID 28838902.
- PMID 14673969.
- S2CID 21925882.
- PMID 26077399.
- PMID 33528002.
- ^ PMID 37144946.
- PMID 15728420.
- OCLC 663444979.
- ^ "giant cell arteritis" at Dorland's Medical Dictionary
External links
- Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza A, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B (1 March 2020). "British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis". Rheumatology. 59 (3). Oxford, England: e1–e23. PMID 31970405.